Core Viewpoint - INOVIO is actively participating in several upcoming scientific and investor conferences to showcase its advancements in DNA medicines aimed at treating HPV-associated diseases, cancer, and infectious diseases [1] Conference Participation - INOVIO will present at the American Association for Cancer Research Immuno-Oncology Conference on February 18, focusing on the treatment of Recurrent Respiratory Papillomatosis (RRP) with DNA immunotherapy INO-3107 [1] - The company will also participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, featuring a fireside chat webcast [1] - At the Festival of Biologics on March 4, INOVIO will present findings on the safety and pharmacokinetics of SARS-CoV-2 DNA-Encoded Monoclonal Antibodies in a Phase 1 trial [1] - The Citizens Life Sciences Conference on March 10 will include another fireside chat with INOVIO's management team [1] Company Overview - INOVIO is a biotechnology company dedicated to developing and commercializing DNA medicines that empower the body to produce its own disease-fighting tools [1]

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. for the period between October 10, 2023, and December 26, 2025, indicating potential legal challenges for the company [1]. Company Overview - Inovio Pharmaceuticals, Inc. is described as a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating and protecting individuals from diseases, including those associated with human papillomavirus (HPV) [1].

Core Insights - INOVIO, a biotechnology company, focuses on developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases [1] Conference Participation - INOVIO will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, from 8:30 to 8:55 AM ET, featuring a fireside chat format [1] - The company will also attend the Oppenheimer Movers in Rare Disease Summit on December 11, from 12:05 to 12:25 PM ET, where it will present in a panel format focusing on rare disease companies with potential stock-moving catalysts [1] - INOVIO's management team will conduct one-on-one meetings with investors during these conferences [1]

Core Insights - INOVIO is set to release its third quarter 2025 financial results on November 10, 2025, after market close, followed by a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update [1]. Company Overview - INOVIO is a biotechnology company focused on developing and commercializing DNA medicines aimed at treating and protecting individuals from HPV-related diseases, cancers, and infectious diseases [3]. - The company's technology is designed to optimize the design and delivery of innovative DNA medicines that enable the body to produce its own disease-fighting tools [3]. Event Details - The live webcast for the financial results will be available online and will include a live Q&A session with analysts, with the event being archived for 90 days for replay [2].

Core Insights - INOVIO is participating in a virtual fireside chat at the upcoming Stephens Biotechnology Virtual Fireside Chat Conference, where management will also hold one-on-one meetings with investors [1][2]. Company Overview - INOVIO is a biotechnology company focused on developing and commercializing DNA medicines aimed at treating and protecting individuals from HPV-related diseases, cancer, and infectious diseases [3][5]. - The company's technology enhances the design and delivery of innovative DNA medicines that instruct the body to produce its own disease-fighting tools [3].

Core Insights - INOVIO is a biotechnology company focused on developing and commercializing DNA medicines for HPV-associated diseases, cancer, and infectious diseases [3] Group 1: Conference Details - INOVIO announced a pre-recorded presentation will be available on demand as part of the H.C. Wainwright 27th Annual Global Investment Conference in New York [1] - The presentation will be accessible starting September 5, 2025, at 7:00 AM ET and will remain available for 90 days [2] - INOVIO's management team will also conduct in-person one-on-one meetings with investors during the conference [1] Group 2: Company Overview - INOVIO's technology focuses on optimizing the design and delivery of innovative DNA medicines that enable the body to produce its own disease-fighting tools [3] - The company aims to help treat and protect individuals from HPV-related diseases, cancer, and infectious diseases [3]

Core Viewpoint - INOVIO Pharmaceuticals, Inc. has announced a public offering of 14,285,715 shares of common stock and accompanying Series A and Series B warrants, priced at $1.75 per share, aiming to raise approximately $25 million before expenses [1][2]. Group 1: Offering Details - The public offering includes 14,285,715 shares of common stock and warrants to purchase an equal number of shares at an exercise price of $1.75 [1]. - The offering is expected to close on or about July 7, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 2,142,857 additional shares and warrants at the public offering price [1]. Group 2: Financial Aspects - Gross proceeds from the offering are anticipated to be approximately $25 million, excluding underwriting discounts and commissions [2]. - The offering is being managed by Piper Sandler & Co. as the sole active book-running manager, with Oppenheimer & Co. Inc. as a passive bookrunner [2]. Group 3: Regulatory Information - A shelf registration statement for the offering was filed with the SEC on November 9, 2023, and was declared effective on January 31, 2024 [3]. - The offering is conducted through a written prospectus and prospectus supplement available on the SEC's website [3]. Group 4: Company Overview - INOVIO is focused on developing and commercializing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases [5]. - The company's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [5].

Core Points - INOVIO, a biotechnology company, focuses on developing and commercializing DNA medicines for HPV-associated diseases, cancers, and infectious diseases [1][3] - The company will release its first quarter 2025 financial results on May 13, 2025, after market close [1] - A live conference call and webcast will follow the financial results release at 4:30 p.m. ET, including a Q&A session with analysts [1][2] Company Overview - INOVIO's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [3] - The company aims to protect and treat individuals from HPV-related diseases and other infectious diseases through its innovative approach [3]